ArticleBMC cardiovascular disorders2025
Patterns of beta-blocker use and dose optimization among ambulatory heart failure patients with reduced ejection fraction (HFrEF) attending public hospitals in Northeast Ethiopia: a multi-center cross-sectional study.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of bisoprolol combined with torasemide on cardiac electrophysiology in patients with acute myocardial infarction and heart failure.Frontiers in physiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEvidence-based beta-blockers are essential in managing heart failure with reduced ejection fraction (HFrEF) and are known to improve cardiovascular outcomes. Despite robust nascent guideline recommendations, studies indicate that beta-blockers are often underutilized or administered below target doses. This shivery issue is particularly relevant in Ethiopia, where comprehensive evaluations of beta-blocker utilization and dosing practices are limited. The Northeast region, specifically Dessie, remains underexplored in this context.
objectiveThis study aimed to evaluate the appropriate usage trend and dose optimization of beta-blockers among HFrEF patients attending ambulatory clinics of Dessie Comprehensive Specialized Hospital (DCSH) and Boru Meda General Hospital (BMH), Dessie, Ethiopia, 2024 G.C.
methodsA cross-sectional, multi-center study was conducted from February 1 to July 30, 2024, involving 200 randomly selected adult patients with confirmed HFrEF (120 from DCSH and 80 from BMH), who had at least 6-month regular follow-up visits at their respective ambulatory clinics. The study rigorously followed the latest (2022) American Heart Association (AHA) guideline recommendation. Patient's medical records was reviewed to gather the necessary data. A logistic regression analysis was performed to identify factors associated with beta-blocker use. Statistical significance was declared at p-value < 0.05.
resultsAmong the 200 patients, 88% were prescribed beta-blockers. About 15% of the patients were not receiving beta-blockers whereas they are indicated. Out of the total, 96.5% received guideline-recommended beta-blockers, with bisoprolol being the most common (65%), followed by metoprolol (29%) and carvedilol (3%). Only 13% of beta-blocker users were on optimal doses, with average daily doses of 27.9 mg for metoprolol succinate, 10.0 mg for carvedilol, and 4.8 mg for bisoprolol. Factors positively associated with beta-blocker use included Angiotensin Converting Enzyme Inhibitor use (AOR: 15.48, 95% CI: 2.11-113.54, p = 0.007), and taking multiple medications (AOR: 7.12, 95% CI: 1.54-33.02, p = 0.012), while ingestion of secondary prevention agents (AOR: 0.05, 95% CI: 0.01-0.98, p = 0.048) and male gender (AOR: 0.08, 95% CI: 0.01-0.47, p = 0.005) were negatively associated. Baseline ejection fraction of 25-40% (AOR: 5.44, 95% CI: 1.09-27.12, P = 0.039) was a sole predictor for sub-optimal beta-blocker use.
conclusionAlthough most patients with HFrEF were prescribed evidence-based beta-blockers, only a limited number reached the optimal dosing levels. It is crucial to align clinical practice with the latest guidelines, prioritize ongoing research, and enhance educational efforts for both healthcare providers and patients. By doing so, it is possible to significantly improve the effective utilization of beta-blockers, ultimately leading to better patient outcomes in this region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.